Intermethod Variability in TSH-Receptor Antibody Measurement: Implication for the Diagnosis of Graves Disease and for the Follow-Up of Graves Ophthalmopathy
- 1 January 2009
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 55 (1) , 183-186
Abstract
Background: We compared the analytical and clinical performance of 3 porcine thyroid receptor antibody (TRAb) methods (1 second- and 2 new third-generation systems) with the conventional TRAb assay based on the human recombinant TSH receptor (hTRAK). Patients and Methods: We obtained sera from 86 patients with untreated Graves disease (GD) and 71 healthy controls. We measured TRAb concentrations by radioreceptor assay using the hTRAK (Brahms) or the porcine TSH receptor (pRRA) from Beckman-Coulter, by electrochemiluminescence immunoassay (ECLIA) with the Elecsys/Cobas (Roche), and by ELISA using the Medizym TRAb clone (Medipan). Results: Between-run assay imprecision was ≤10% and ≤7.6% for hTRAK and ECLIA, but reached 14% and 14.9% for ELISA and pRRA, respectively. Maximal specificity and sensitivity close to 100% were obtained for hTRAK, ECLIA, and ELISA. pRRA failed to detect positive TRAbs in 5 GD patients. Although calibrated against the same reference standard 90/672, the assays displayed a high intermethod variability. The results were significantly higher by ECLIA and lower by ELISA and pRRA compared with hTRAK. Patients with ophthalmopathy had higher TRAb results by ELISA and pRRA than those without eye disease. Conclusions: Second- and third-generation TRAb assays had similar diagnostic sensitivities in the diagnostic evaluation of GD. Despite the use of the same reference standard for calibration, high intermethod variability in TRAb assay results was seen in untreated GD patients. Assay harmonization is necessary for correct interpretation in the follow-up of Graves ophthalmopathy.Keywords
This publication has 12 references indexed in Scilit:
- Comparison of M22-based ELISA and Human-TSH-Receptor-based Luminescence Assay for the Measurement of Thyrotropin Receptor Antibodies in Patients with Thyroid DiseasesHormone and Metabolic Research, 2008
- The Thyrotropin Receptor in Graves' DiseaseThyroid®, 2007
- Stimulating and Blocking Thyroid-Stimulating Hormone (TSH) Receptor Autoantibodies from Patients with Graves’ Disease and Autoimmune Hypothyroidism Have Very Similar Concentration, TSH Receptor Affinity, and Binding SitesThe Journal of Clinical Endocrinology & Metabolism, 2007
- A New Assay for Thyrotropin Receptor AutoantibodiesThyroid®, 2004
- TSH‐receptor antibody measurement for differentiation of hyperthyroidism into Graves' disease and multinodular toxic goitre: a comparison of two competitive binding assaysClinical Endocrinology, 2001
- Clinical validity of a new commercial method for detection of TSH-receptor binding antibodies in sera from patients with Graves’ disease treated with antithyroid drugsClinica Chimica Acta, 2001
- Clinical value of a new TSH binding inihibitory activity assay using human TSH receptors in the follow‐up of antithyroid drug treated Graves' disease. Comparison with thyroid stimulating antibody bioassayClinical Endocrinology, 2001
- Association of thyrotrophin receptor antibodies with the clinical features of Graves' ophthalmopathyClinical Endocrinology, 2000
- Autoantibodies to the Thyrotropin ReceptorEndocrine Reviews, 1988
- AN IMPROVED RADIORECEPTOR ASSAY FOR TSH RECEPTOR ANTIBODIESClinical Endocrinology, 1982